Background: Major events, such as Hurricanes Irma and Maria and the coronavirus disease 2019 (COVID‐19) pandemic disrupted Puerto Rico's health system. Lack of access to colorectal cancer (CRC) screening services may have impeded timely diagnosis. The authors examined the impact of these events on CRC incidence in Puerto Rico.Methods: The Puerto Rico Central Cancer Registry database allowed the authors to obtain CRC cases from 2012 to 2021. An interrupted time‐series analysis was performed to examine changes in CRC incidence immediately after and during the periods after the hurricanes and the pandemic. Analysis periods included: pre‐hurricanes, post‐hurricanes, and post‐COVID‐19 lockdown restrictions.Results: We observed a level change of −8.3 CRC cases was observed in the month the hurricanes struck Puerto Rico, corresponding to an immediate decrease of 17.5%. After a slight upward trend, a second decline of 39.4 CRC cases was estimated after the COVID‐19 lockdown restrictions, representing an immediate change of −24.2%. By the end of the study, the estimated numbers of patients with early stage CRC patients and those aged 50–75 years did not reach the expected numbers. In addition, CRC cases in patients with late‐stage disease and in those aged younger than 50 years and aged 76 years and older exceeded the expected numbers.Conclusions: Hurricanes Irma and Maria and the COVID‐19 pandemic caused a decrease in CRC incidence in Puerto Rico. This analysis suggests that limited access to CRC screening services during these events likely hindered CRC diagnoses. To fully understand the long‐term effects, monitoring of CRC trends will be necessary in the coming years.
Endometrial cancer poses a significant health concern in Puerto Rico, where it ranks as the primary gynecological malignancy among women. This study evaluates concordance with the National Comprehensive Cancer Network (NCCN) guidelines for endometrial cancer first treatment in Puerto Rican women and its association with 5-year overall survival. Data on patients with endometrial cancer diagnosed between 2009 and 2015 was obtained from the Puerto Rico Central Cancer Registry, which is linked to the Puerto Rico Health Insurance Linkage database (n = 2114). The association between receiving guideline-concordant first treatment and clinical, socioeconomic, and health system factors was evaluated using logistic regression. The 5-year overall survival was calculated using the Kaplan-Meier method. Cox proportional hazard regression models were used to estimate hazard ratios and 95 % confidence intervals (CIs) for associations between guideline-concordant first treatment and overall survival. In our cohort, 53.9 % of patients received guideline-concordant first treatment. Receiving care at a Commission on Cancer-accredited center, being evaluated by a gynecologist-oncologist, and possessing private insurance enhanced the likelihood of receiving guideline-concordant first treatment. In the Cox regression models, receiving guideline-concordant first treatment was associated with a lower mortality risk (HR: 0.72, 95 % CI: 0.59-0.89). Guideline-concordant first treatment is a strong predictor of improved survival rates in endometrial cancer. Given that guidelines based on scientific evidence have been demonstrated to enhance patient outcomes, we must understand and promote the factors contributing to their adoption.
Over the past decades, the rising incidence rates of endometrial cancer have made it a significant public health concern for women worldwide. Treatment strategies for endometrial cancer vary based on several factors such as stage, histology, the patient’s overall health, and preferences. However, limited amount of research on treatment patterns and potential correlations with sociodemographic characteristics among Hispanics is available. This study analyzes the treatment patterns for patients diagnosed with endometrial cancer in Puerto Rico. A secondary database analysis was performed on endometrial cancer cases reported to the Puerto Rico Central Cancer Registry-Health Insurance Linkage Database from 2009 to 2015 (n = 2,488). The study population’s sociodemographic and clinical characteristics were described, along with an overview of the therapy options provided to patients receiving care on the island. Logistic regression models were used to evaluate the association of sociodemographic/clinical characteristics with treatment patterns stratified by risk of recurrence. In our cohort, most patients were insured through Medicaid and had a median age of 60 years. Almost 90% of patients received surgery as the first course of treatment. Surgery alone was the most common treatment for low-risk patients (80.2%). High-risk patients were more likely to receive surgery with radiotherapy and chemotherapy (24.4%). Patients with Medicare insurance were five times (HR: 4.84; 95% CI: 2.45–9.58; p < 0.001) more likely to receive surgery when compared with patients insured with Medicaid. In contrast, those with private insurance were twice as likely to receive surgery (HR: 2.38; 95% CI: 1.40–4.04; p = 0.001) when compared to those with Medicaid. These findings provide insight into the treatment patterns for endometrial cancer in Puerto Rico and highlight the importance of considering factors such as disease risk when making treatment decisions. Addressing these gaps in treatment patterns can contribute to effective management of endometrial cancer.
The five-year relative survival (RS) for cervical cancer in Puerto Rico and the United States (US) is less than 70%. To assess survival trends in the past decades, we compared the five-year RS of cervical cancer in Puerto Rico and in the US. Data was obtained from the Puerto Rico Central Cancer Registry and the Surveillance, Epidemiology, and End Results Program. We included microscopically confirmed cases of cervical carcinoma between 2000 and 2021. The five-year RS trends were analyzed with Joinpoint regression models using the JPSurv software, which estimated the Average Absolute Change in Survival (AAC_S). Puerto Rico showed a lower five-year RS than US overall across the study period. In the US, the AAC_S was -0.78 for patients diagnosed between 2000 and 2003 (95%CI: -1.32 to -0.23), -0.22 for 2003-2013 (95%CI: -0.36 to -0.08), and 0.25 for 2013-2021 (95%CI: 0.01-0.49). In Puerto Rico, the AAC_S was -0.03 for 2000-2011 (95%CI: -0.56-0.51), 1.71 for 2011-2016 (95%CI: 0.60-2.83), and -1.10 for 2016-2021 (95%CI: -3.12-0.92). Puerto Rico shows poorer cervical cancer five-year RS than the US. Increased five-year RS was observed in the US overall population after 2013. In Puerto Rico, improvements in five-year RS were observed after 2011, but these were halted after 2016. This finding may suggest that barriers to accessing care during periods of extreme events, such as the convergence of the 2017 hurricanes and the 2020 COVID-19 pandemic challenges, likely affected survival trends from 2016 to 2021. Future research should further characterize barriers to improve cervical cancer survival.
Background: Hospice services play an important role in end-of-life (EoL) care. In Puerto Rico, Medicaid had no provisions for hospice care until July 2024, representing a significant public health challenge. This study examined the association between hospice coverage policy and EoL outcomes among patients with cancer enrolled in Medicaid. Methods: This population-based retrospective cohort study analyzed data of cancer patients enrolled in Medicaid from the Puerto Rico Central Cancer Registry between 2011 and 2022 who died of cancer between 2016 and 2022. Hospice enrollment was categorized into timeframes before death: 1-7, 8-14, 15-30, 31-90, 91-120, and 121-180 days. We compared total costs, healthcare utilization, and death in acute settings by hospice enrollment status. Results: Of 4481 patients in the study, 21.7% were enrolled in hospice. Non-hospice-enrolled patients had higher healthcare expenditures for the last 7 ($548; 95% confidence interval [CI ]= $166 to $931), 14 ($1619; 95% CI = $894 to $2344), 30 ($3410; 95% CI = $2263 to $4557), 90 ($4896; 95% CI = $1987 to $7804), 120 ($6171; 95% CI = $61 to $12 281), and 180 ($19 291; 95% CI = $10 851 to $27 731) days than hospice-enrolled patients. Emergency department visit rates and hospitalization rates were higher for all periods (P < .05) for non-hospice-enrolled patients than for hospice-enrolled patients. Similarly, non-hospice-enrolled patients had a higher likelihood of dying in acute settings (P < .05). Conclusion: Hospice enrollment among Medicaid enrollees was associated with lower health expenditure, lower healthcare resource utilization, and a lower likelihood of mortality in an acute setting. The recent policy change to include hospice services coverage in Puerto Rico Medicaid is a positive step that must be sustained beyond 2027.